Company research
Pulsenmore Ltd.
CIK 2064764Updated Sep 24, 2026
SecurityPLSM · NASDAQ · equity
PLSM price & chart
Loading TradingView…
NASDAQ:PLSM on TradingView ↗About the company
We are an emerging medical device company focused on research, development, manufacture, marketing, and sale of innovative, non-invasive portable ultrasound solutions that provide significant healthcare benefits by utilizing next-generation technology for home use. We currently have two primary products, the Pulsenmore ES and the Pulsenmore FC, and an additional third portable ultrasound solution that is in earlier developmental stages, the Pulsenmore MC. We collectively refer to our products as the “Pulsenmore Products”. The Pulsenmore Products open the door to a new market in the field of ultrasound - performing home scans in gynecology as well as in various other fields such as pulmonary, cardiology, and urology.
In the news
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor ↗
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S. News provided by Pulsenmore Ltd. Jan 21, 2026, 07:30 ET Share this article Share to X Share this article Share to X RAMAT GAN, Israel , Jan. 21, 2026 /PRNewswire/ -- Pulsenmore Ltd. ( ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | -4,970,000Source | -36,736,000Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -74,000Source | -2,947,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 209,000Source | 1,388,000Source |
| GeneralAndAdministrativeExpenseUSD | 5,230,000Source | 15,344,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 369,000Source | 1,167,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cost of Goods and Services Sold | — | — |
| Total RevenueUSD | 12,547,000Source | 9,661,000Source |
| Additional Financial Items | ||
| BasicEarningsLossPerShareUSD per share | 0.77Source | 5.76Source |
| DepreciationAndAmortisationExpenseUSD | 879,000Source | 2,852,000Source |
| DepreciationRightofuseAssetsUSD | 303,000Source | 1,011,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.77Source | 5.76Source |
| EmployeeBenefitsExpenseUSD | 414,000Source | 1,334,000Source |
| FinanceIncomeUSD | 1,109,000Source | 5,963,000Source |
| GeneralAndAdministrativeExpenseUSD | 5,230,000Source | 15,344,000Source |
| GrossProfitUSD | 10,559,000Source | 3,577,000Source |
| IncomeTaxExpenseContinuingOperationsILS | 1,000Source | -56,000Source |
| InterestExpenseUSD | 2,265,000Source | 540,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 99,000Source | 492,000Source |
| NetForeignExchangeLossUSD | 879,000Source | — |
| ProfitLossBeforeTaxUSD | -4,970,000Source | -36,792,000Source |
| ResearchAndDevelopmentExpenseUSD | 5,439,000Source | 20,130,000Source |